| Systematic (IUPAC) name | |
|---|---|
| 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl- N-(1-piperidyl)pyrazole-3-carboxamide |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 183232-66-8 |
| ATC code | ? |
| PubChem | CID 2125 |
| IUPHAR ligand | 744 |
| ChemSpider | 2040 |
| ChEMBL | CHEMBL285932 |
| Chemical data | |
| Formula | C22H21Cl2IN4O |
| Mol. mass | 555.238 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
AM-251 is an inverse agonist at the CB1 cannabinoid receptor. AM-251 is structurally very close to SR141716A (rimonabant), which both are biarylpyrazole cannabinoid receptor antagonists. In AM-251 the p-chloro group attached to the phenyl substituent at C-5 of the pyrazole ring is replaced with a p-iodo group. The resulting compound exhibits slightly better binding affinity for the CB1 receptor (with a Ki value of 7.5nM) than SR141716A, which has a Ki value of 11.5nM, AM-251 is, however, about two-fold more selective for the CB1 receptor when compared to SR141716A.[1]
|
|||||||||||||||||||||||